Published in Arthritis Rheum on February 15, 2005
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int (2011) 1.64
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2006) 1.47
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis (2006) 1.19
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis (2008) 1.15
Ocular Sarcoidosis. Clin Chest Med (2015) 1.13
Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol (2008) 1.05
Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol (2007) 1.03
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol (2009) 1.02
Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol (2013) 0.99
The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol (2010) 0.95
Pediatric uveitis. J Ophthalmic Vis Res (2011) 0.94
Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J (2014) 0.93
[Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy]. Ophthalmologe (2016) 0.90
Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol (2013) 0.90
Biologic agents in inflammatory eye disease. J Ophthalmic Vis Res (2011) 0.90
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr (2012) 0.88
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr (2010) 0.88
Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol (2010) 0.87
Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int (2006) 0.86
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84
Juvenile idiopathic arthritis: management and therapeutic options. Ther Adv Musculoskelet Dis (2012) 0.83
Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol (2015) 0.82
Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J (2016) 0.81
Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol (2014) 0.81
[Therapy for childhood uveitis: biologics: too often--too late?]. Ophthalmologe (2011) 0.80
Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev (2014) 0.80
Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics (2009) 0.80
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis (2006) 0.80
Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int (2015) 0.78
Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. Rheumatology (Oxford) (2016) 0.78
[Uveitis in juvenile idiopathic arthritis]. Z Rheumatol (2010) 0.77
The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. Paediatr Drugs (2015) 0.77
Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) (2015) 0.76
Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Des Devel Ther (2014) 0.75
Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med J (2017) 0.75
Assessment of inflammatory response in a study of uveitis associated with juvenile idiopathic arthritis: comment on the article by Smith et al. Arthritis Rheum (2005) 0.75
Reconsidering treatment options in childhood uveitis. Br J Ophthalmol (2007) 0.75
Clinical trials in noninfectious uveitis. Int Ophthalmol Clin (2015) 0.75
Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res Notes (2014) 0.75
[Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)]. Z Rheumatol (2005) 0.75
[Current news from the BIKER register]. Z Rheumatol (2014) 0.75
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med (2006) 5.74
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol (2003) 4.52
Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care (2004) 4.39
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A (2006) 3.49
Resolution of sister telomere association is required for progression through mitosis. Science (2004) 3.13
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr Biol (2004) 2.45
TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev (2003) 2.27
Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol (2002) 2.22
Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19
Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ (2007) 2.19
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Tankyrase function at telomeres, spindle poles, and beyond. Biochimie (2007) 2.12
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol (2006) 2.10
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci U S A (2011) 2.10
How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol (2006) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum (2009) 2.02
The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology (2004) 2.01
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY. Retina (2016) 1.92
Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS One (2008) 1.86
mRNA decay factor AUF1 maintains normal aging, telomere maintenance, and suppression of senescence by activation of telomerase transcription. Mol Cell (2012) 1.86
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol (2002) 1.70
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
Integrating medical management with diabetes self-management training: a randomized control trial of the Diabetes Outpatient Intensive Treatment program. Diabetes Care (2003) 1.68
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J Biol Chem (2002) 1.57
Trauma resuscitation errors and computer-assisted decision support. Arch Surg (2011) 1.57
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis. Biochem J (2005) 1.53
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol (2008) 1.51
Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol (2005) 1.48
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 1.48
LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) (2013) 1.46
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
Protein requirements for sister telomere association in human cells. EMBO J (2007) 1.45
Tankyrase 2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping. Mol Cell Biol (2006) 1.45
Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells. J Cell Biol (2009) 1.43
Increased nerve and blood vessel ingrowth associated with proteoglycan depletion in an ovine anular lesion model of experimental disc degeneration. Spine (Phila Pa 1976) (2002) 1.39
Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A (2011) 1.33
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology (2003) 1.30
Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J Clin Microbiol (2002) 1.27
Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol (2003) 1.27
ToF-SIMS imaging and depth profiling of HeLa cells treated with bromodeoxyuridine. Surf Interface Anal (2011) 1.22
A role for heterochromatin protein 1γ at human telomeres. Genes Dev (2011) 1.22
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res (2007) 1.18
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Cytokine and chemokine levels in tears from healthy subjects. Acta Ophthalmol (2010) 1.14
Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol (2008) 1.12
Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J Cell Biol (2009) 1.11
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol (2004) 1.11
The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf (2010) 1.11
Conquering the Sahara and Arabian deserts: systematics and biogeography of Stenodactylus geckos (Reptilia: Gekkonidae). BMC Evol Biol (2012) 1.10
Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study. Histochem Cell Biol (2005) 1.08
Familial eosinophilia: a benign disorder? Blood (2004) 1.08
Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina (2009) 1.07
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget (2013) 1.07
Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med (2005) 1.07
Glycosylation of sputum mucins is altered in cystic fibrosis patients. Glycobiology (2007) 1.07
Burns caused by steam inhalation for respiratory tract infections in children. BMJ (2004) 1.07
Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med (2012) 1.06
Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 1.06
Sarcoidosis in chronic granulomatous disease. Pediatrics (2006) 1.04
Recognition and labeling of delirium symptoms by intensivists: does it matter? Intensive Care Med (2007) 1.04
Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina (2014) 1.04
Spatial and temporal localization of transforming growth factor-beta, fibroblast growth factor-2, and osteonectin, and identification of cells expressing alpha-smooth muscle actin in the injured anulus fibrosus: implications for extracellular matrix repair. Spine (Phila Pa 1976) (2002) 1.03
Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med (2003) 1.03
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.02
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol (2009) 1.02
Randomized controlled trial to assess the short-term effectiveness of tailored web- and text-based facilitation of smoking cessation in primary care (iQuit in practice). Addiction (2014) 1.01
The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Biol Chem (2006) 1.01
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci (2006) 0.98
Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation. Mol Cell Biol (2004) 0.97
Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol (2012) 0.96
Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol (2010) 0.95
Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen (2005) 0.95
Adult genital surgery for intersex: a solution to what problem? J Health Psychol (2005) 0.94
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials. Clin Ophthalmol (2011) 0.93
Getting evidence into practice in developing countries. Evid Based Cardiovasc Med (2006) 0.93
Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol (2011) 0.93
Intracerebral microdialysis during deep brain stimulation surgery. J Neurosci Methods (2010) 0.93
Identifying individual cell types in heterogeneous cultures using secondary ion mass spectrometry imaging with C60 etching and multivariate analysis. Anal Chem (2012) 0.92